The combination of navitoclax and ruxolitinib simultaneously inhibits two essential mechanisms that market myelofibrosis, leading to an advancement in symptom Handle and beneficial adjustments in reaction biomarkers in patients with higher-threat ailment. Skip to principal content Thanks for checking out mother nature.com. You might be employing a browser Edition with https://barbarap888cnx0.wikibyby.com/user